Argus Research maintains AbbVie at Buy

What happened

Argus Research maintained its Buy rating on AbbVie, meaning it kept its positive recommendation rather than changing it. The article also lists five recent analyst notes, whose price targets range from $295 to $346.

Confirmed

Global impact / market context

A maintained Buy rating signals that Argus Research has not changed its positive view, but it does not itself change AbbVie’s sales, costs, or cash available. The other listed ratings and targets show analysts differ in their assessments.

Analyst inference

The article reports five analyst notes from the past 30 days, with targets spanning $295 to $346 and ratings ranging from Neutral to positive. This is a snapshot of analyst opinion, not evidence of a change in AbbVie’s business results.

Confirmed

What to watch

1. Watch for any later Argus Research rating change; a move away from Buy would indicate its stated view has shifted, though the article gives no reason for this rating. Analyst inference
2. Compare future analyst targets with the reported $295–$346 range to see whether expectations are changing; the article does not establish that any target will be reached. Analyst inference
3. Look for company updates on sales, costs, or cash available, since operating results can provide evidence about the business that analyst ratings alone do not give. Analyst inference

Evidence

• Original source link unavailable